A pharmacovigilance study published online in Gut and Liver on 2 September pooled the national adverse-event databases of the United States, Japan and Canada and found gastroesophageal reflux disease reported roughly two to five times more often for GLP-1 drugs than for a comparator diabetes drug class. The signal held in all three countries. It … Read more
The Federal Aviation Administration published a notice of proposed rulemaking on 4 September 2026 that would let pilots whose type 2 diabetes is controlled without insulin be certified by an aviation medical examiner at their examination, rather than through the FAA Authorization for Special Issuance process. The proposal would strike the phrase “or any other … Read more
A study of 63,215 patients with pre-existing neuropsychiatric conditions, published on 1 September, found semaglutide associated with broadly lower rates of neuropsychiatric events over two years than metformin, SGLT2 inhibitors or DPP-4 inhibitors. Within the semaglutide group, patients who reached higher doses had fewer such events afterwards — the inverse of the dose-toxicity pattern implied … Read more
A new cohort study adds to a now-consistent finding: people taking semaglutide or tirzepatide are diagnosed with non-scarring hair loss more often than matched non-users. This is not a fringe signal — hair loss is printed on the Wegovy label, among the adverse reactions occurring in at least 2% of treated patients and more often … Read more
The Spanish Menopause Society published an expert position statement on 25 August covering the use of GLP-1 and dual incretin medications in peri- and postmenopausal women with overweight or obesity. It sets out 20 positions across body composition, cardiometabolic risk, musculoskeletal health, monitoring and interaction with hormone therapy. The most useful thing in it, for … Read more
A systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo. … Read more
A case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also … Read more
Eli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up … Read more